Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Daniel M. F. Claassens, Thomas O. Bergmeijer, Gerrit J. A. Vos, Renicus S. Hermanides, Arnoud W. J. van 't Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M. Tjon Joe Gin, Folkert W. Asselbergs, Arend Mosterd, Jean-Paul R. Herrman, Willem J. M. Dewilde, Paul W. A. Janssen, Johannes C. Kelder, Bakhtawar K. Mahmoodi, Vera H. M. Deneer, Jurrien M. ten Berg*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number009434
Pages (from-to)402-411
Number of pages10
JournalCirculation-Cardiovascular Interventions
Volume14
Issue number4
DOIs
Publication statusPublished - Apr 2021

Keywords

  • acute coronary syndrome
  • clopidogrel
  • genetic testing
  • myocardial infarction
  • percutaneous coronary intervention
  • pharmacogenetics
  • ticagrelor
  • MYOCARDIAL-INFARCTION
  • CARDIOVASCULAR OUTCOMES
  • GUIDELINES
  • VARIANT
  • CYP2C19-ASTERISK-17
  • POLYMORPHISMS
  • TASK-FORCE
  • ANTIPLATELET TREATMENT
  • ASSOCIATION
  • ARTERY-DISEASE

Cite this